The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN a ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.